类风湿关节炎持续缓解后依那西普或甲氨蝶呤减停研究
371例接受甲氨蝶呤联合依那西普治疗的类风湿关节炎患者中,253例经24周开放期维持SDAI≤3.3的缓解后进入48周双盲期,随机分为甲氨蝶呤单药组(n=101)、依那西普单药组(n=101)和联合治疗组(n=51)。第48周时,依那西普单药组维持SDAI缓解且无疾病恶化的患者比例显著高于甲氨蝶呤单药组(49.5% vs 28.7%,P=0.004),联合治疗组也显著高于甲氨蝶呤单药组(52.9% vs 28.7%,P=0.006)。依那西普单药维持缓解的疗效优于甲氨蝶呤单药,与联合治疗相似,且接受补救治疗的患者中70-80%可重新获得SDAI缓解。
要点
- 依那西普单药维持缓解优于甲氨蝶呤单药(49.5% vs 28.7%)。
- 联合治疗维持缓解优于甲氨蝶呤单药(52.9% vs 28.7%)。
- 甲氨蝶呤单药组疾病恶化时间更短(P<0.001)。
核心结论
- 依那西普单药维持缓解的疗效优于甲氨蝶呤单药,与联合治疗相似。
- 接受补救治疗的患者中多数可重新获得SDAI定义的缓解。
研究设计与样本
- 371例接受甲氨蝶呤联合依那西普治疗的类风湿关节炎患者中,253例经24周开放期维持SDAI≤3.3的缓解后进入48周双盲期。
- 253例随机分为甲氨蝶呤单药组(n=101)、依那西普单药组(n=101)和联合治疗组(n=51),疾病恶化者接受联合方案补救治疗。
主要发现
- 第48周时,依那西普单药组维持SDAI缓解且无疾病恶化的患者比例显著高于甲氨蝶呤单药组(49.5% vs 28.7%,P=0.004)。
- 联合治疗组维持SDAI缓解的患者比例显著高于甲氨蝶呤单药组(52.9% vs 28.7%,P=0.006)。
- 甲氨蝶呤单药组疾病恶化时间短于依那西普单药组和联合治疗组(各P<0.001)。
- 接受补救治疗的患者中,各组70-80%重新获得SDAI定义的缓解。
关键数值与推荐
- 缓解定义为SDAI评分≤3.3。
- 主要终点为第48周依那西普单药组与甲氨蝶呤单药组维持SDAI缓解且无疾病恶化的患者比例。
临床怎么用
- 对于联合治疗后持续缓解的类风湿关节炎患者,减停药物时可考虑保留依那西普单药而非甲氨蝶呤单药以维持缓解。
- 疾病恶化后重新启用联合方案补救治疗,多数患者可重新获得缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with rheumatoid arthritis (RA) in whom remission is achieved following combination therapy with methotrexate plus etanercept face an ongoing medication burden. This study was undertaken to investigate whether sustained remission achieved on combination therapy can be maintained with either methotrexate or etanercept monotherapy, as assessed following discontinuation of one or the other medication from the combination. METHODS: Of the 371 adult patients with RA who received combination therapy with methotrexate plus etanercept, remission (defined as a Simplified Disease Activity Index [SDAI] score of ≤3.3) was sustained in 253 patients through a 24-week open-label period. These 253 patients then entered a 48-week, double-blind period and were randomized to receive either 1) methotrexate monotherapy (n = 101), 2) etanercept monotherapy (n = 101), or 3) methotrexate plus etanercept combination therapy (n = 51). Patients who subsequently experienced disease-worsening received rescue therapy with the combination regimen at the same dosages as used in the initial run-in period. The primary end point was the proportion of patients in whom SDAI-defined remission was maintained without disease-worsening at week 48 in the etanercept monotherapy group as compared to the methotrexate monotherapy group. Secondary end points included time to disease-worsening, and the proportion of patients in whom SDAI-defined remission was recaptured after initiation of rescue therapy. RESULTS: Baseline demographic and clinical characteristics of the RA patients were similar across the treatment groups. At week 48, SDAI-defined remission was maintained in significantly more patients in the etanercept monotherapy group than in the methotrexate monotherapy group (49.5% versus 28.7%; P = 0.004). Moreover, as a secondary end point, sustained SDAI-defined remission was achieved in significantly more patients who received combination therapy than in those who received methotrexate monotherapy (52.9% versus 28.7%; P = 0.006). Time to disease-worsening was shorter in those who received methotrexate monotherapy than in those who received etanercept monotherapy or those who received combination therapy (each P < 0.001 versus methotrexate monotherapy). Among the patients who received rescue therapy, SDAI-defined remission was recaptured in 70-80% in each treatment group. No new safety signals were reported. CONCLUSION: The efficacy of etanercept monotherapy was superior to that of methotrexate monotherapy and similar to that of combination therapy in maintaining remission in patients with RA. SDAI-defined remission was recaptured in most of the patients who were given rescue therapy. These data could inform decision-making when withdrawal of therapy is being considered to reduce treatment burden in patients with well-controlled RA.
引用
- Curtis JR, Emery P, Karis E, et al. Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission. Arthritis Rheumatol. 2021. PMID: 33205906. doi:10.1002/art.41589
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。